Research - Page 11 of 719 Posts on Medivizor

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by Medivizor on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Posted by Medivizor on Mar 5, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effectiveness and safety of combinations of anti-depressive medication for the treatment of diabetic peripheral neuropathic pain (DPNP) in patients with diabetes. The study showed that combination treatment improved pain in these patients and was well tolerated. Some background DPNP occurs in patients...

Reviewing the significance of very low carbohydrate diets in type 2 diabetes.

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effect of very low carbohydrate (VLC) or ketogenic diets (KDs) with higher carbohydrate diets in patients with pre-diabetes or type 2 diabetes (T2D). The data showed that reduced levels of glycated hemoglobin (HbA1c) and triglycerides may occur with VLC or KDs, but with limited advantages over other diets. Some...

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Posted by Medivizor on Mar 5, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study explored the effectiveness and safety of tripterygium glycosides (TG) as a disease-modifying anti-rheumatic drug (DMARD) when combined with conventional DMARDs for treating rheumatoid arthritis (RA). The authors concluded that good safety and better improvements in RA symptoms were observed when TG was combined with a...

Can once-weekly administered semaglutide reduce adipose tissue and fat in patients with type 2 diabetes?

Posted by Medivizor on Mar 5, 2023 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effect of subcutaneous semaglutide (Ozempic) on body composition in patients with type 2 diabetes (T2D). The data showed significant weight loss in these patients after 3 months of semaglutide treatment based on reduced visceral adipose tissue (VAT) thickness and fat mass (FM). Some background T2D is...

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Mar 5, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rezvilutamide (Ariane) versus bicalutamide (Casodex) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that rezvilutamide in combination with ADT significantly improved the...

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Posted by Medivizor on Mar 5, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) either alone or in combination for the treatment of patients with advanced melanoma. The data showed that nivolumab (Opdivo) and ipilimumab (Yervoy) combination therapy was more effective than nivolumab or ipilimumab alone for the treatment of...

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Posted by Medivizor on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of radiotherapy (RT) in patients with HER2+ early-stage breast cancer (BC) after breast-conserving surgery (BCS). The study found that RT improved the survival rates of these patients, especially for those high-risk. Some background BC is categorized based on the absence or...

Comparing the effectiveness of vaginal laser therapy and hyaluronic acid suppositories in women with urogenital atrophy after breast cancer treatment

Posted by Medivizor on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of vaginal laser therapy (VL) and hyaluronic acid suppositories (HAS) in women with urogenital atrophy after having breast cancer (BC) treatment. The data found that both VA therapy and HAS were equally effective in treating urogenital atrophy in these patients. Some background Many women...

Comparing the effects of different physical and rehabilitation therapies in women with overactive bladder

Posted by Medivizor on Mar 5, 2023 in Overactive bladder | 0 comments

In a nutshell The study compared the effects of different physical and rehabilitation therapies in women with overactive bladder (OAB). The study found that percutaneous tibial nerve stimulation (PTNS) alone, a combination of bladder training (BT) with electrical stimulation (ES), and a combination of BT and ES with biofeedback (BF) were effective for...

Evaluating the effectiveness of a luteinizing hormone-based modified GnRH antagonist protocol in patients with normal ovarian response undergoing in vitro fertilization treatment.

Posted by Medivizor on Feb 28, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the clinical and cost-effectiveness of a luteinizing hormone (LH)-based modified gonadotrophin-releasing hormone (GnRH) antagonist protocol in patients with normal ovarian response undergoing in vitro fertilization (IVF) treatment. The data showed that the LH-based modified GnRH antagonist protocol was more...

Research Posts on Medivizor

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness of chemotherapy before surgery for patients with colorectal cancer liver metastases.

Benefits of combination treatment for diabetic peripheral neuropathic pain.

Reviewing the significance of very low carbohydrate diets in type 2 diabetes.

Combining a “herbal” and conventional disease-modifying anti-rheumatic drug for treating rheumatoid arthritis.

Can once-weekly administered semaglutide reduce adipose tissue and fat in patients with type 2 diabetes?

Evaluating the effectiveness and safety of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of immune checkpoint inhibitors either alone or in combination for the treatment of advanced malignant melanoma.

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Comparing the effectiveness of vaginal laser therapy and hyaluronic acid suppositories in women with urogenital atrophy after breast cancer treatment

Comparing the effects of different physical and rehabilitation therapies in women with overactive bladder

Evaluating the effectiveness of a luteinizing hormone-based modified GnRH antagonist protocol in patients with normal ovarian response undergoing in vitro fertilization treatment.

Categories

Recent Posts

Archives

Research Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email